Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NUBAIN vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
3.5–5 hours (terminal elimination half-life); clinically, in hepatic or renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily hepatic via glucuronidation; CYP450 isoenzymes are not significantly involved.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily renal (83% as unchanged drug and glucuronide conjugate); fecal excretion accounts for <5%.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 25–30% bound to plasma proteins (mainly albumin).
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
4–6 L/kg; indicates extensive tissue distribution.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral bioavailability is low (<20%) due to extensive first-pass metabolism; IV, IM, and subcutaneous routes provide 100% bioavailability.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Cr Cl 30-50 m L/min: reduce dose by 50% and administer every 6 hours; Cr Cl <30 m L/min: reduce dose by 75% and administer every 8 hours.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh Class B: reduce dose by 50% and administer every 6 hours; Child-Pugh Class C: reduce dose by 75% and administer every 8 hours.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Children ≥1 year: 0.1-0.2 mg/kg IV, IM, or SC every 3-6 hours as needed; maximum single dose 20 mg.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at 50% of the usual adult dose (5-10 mg) and titrate cautiously; maximum single dose 15 mg due to increased sensitivity and risk of respiratory depression.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of opioid addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of interactions with drugs affecting CYP3A4; risk of serotonin syndrome with concurrent use of serotonergic drugs.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Respiratory depression,Increased intracranial pressure,Hepatic or renal impairment,Biliary tract disease,Concurrent CNS depressants,Opioid dependence (may precipitate withdrawal),Elderly and debilitated patients
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to nalbuphine or any component,Current or suspected opioid dependence (may precipitate acute withdrawal)
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No specific food interactions. Avoid grapefruit juice as it may affect metabolism of certain opioids, though no direct evidence with nalbuphine.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Pregnancy Category C. First trimester: insufficient human data; animal studies show increased skeletal anomalies at high doses. Second and third trimesters: prolonged use may cause neonatal opioid withdrawal syndrome (NOWS); avoid chronic use due to risk of respiratory depression in neonate.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excreted in breast milk; M/P ratio unknown. Use caution due to potential for infant sedation and respiratory depression. American Academy of Pediatrics considers use compatible but monitor for drowsiness and feeding difficulties.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No established dose adjustment guidelines. Pregnancy may increase clearance of opioids; however, Nubain (nalbuphine) has not been systematically studied for pharmacokinetic changes in pregnancy. Use lowest effective dose for shortest duration, avoiding chronic use. In labor, use 10–20 mg IV/IM every 3–6 hours as needed; titrate to maternal pain with fetal monitoring.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
NUBAIN (nalbuphine) is a mixed agonist-antagonist opioid; it can precipitate withdrawal in opioid-dependent patients. It has a ceiling effect for respiratory depression, making it safer than pure agonists in high doses. Onset of action is 2-3 minutes IV, 15 minutes IM/SC; duration is 3-6 hours. Reversal of opioid effects may require higher doses of naloxone due to nalbuphine's strong receptor binding.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they can increase side effects like drowsiness or slow breathing.,Do not drive or operate machinery until you know how NUBAIN affects you; it may cause dizziness or drowsiness.,Do not stop abruptly; withdrawal symptoms may occur (anxiety, sweating, nausea).,If you have a history of opioid dependence, inform your doctor; NUBAIN may cause withdrawal symptoms.,Report any signs of allergic reaction (rash, itching, swelling) or difficulty breathing immediately.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NUBAIN vs ACTIQ, answered by our medical review team.
NUBAIN is a Opioid Analgesic that works by Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NUBAIN and ACTIQ depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NUBAIN is: 10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NUBAIN and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NUBAIN is classified as Category C. Pregnancy Category C. First trimester: insufficient human data; animal studies show increased skeletal anomalies at high doses. Second and third trimesters: prolonged use may cause. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.